loading
Bolt Biotherapeutics Inc stock is traded at $5.92, with a volume of 928. It is up +0.17% in the last 24 hours and down -2.47% over the past month. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$5.91
Open:
$5.91
24h Volume:
928
Relative Volume:
0.05
Market Cap:
$12.73M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-3.235
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
+2.96%
1M Performance:
-2.47%
6M Performance:
-49.68%
1Y Performance:
-59.86%
1-Day Range:
Value
$5.91
$6.04
1-Week Range:
Value
$5.52
$6.21
52-Week Range:
Value
$5.20
$15.60

Bolt Biotherapeutics Inc Stock (BOLT) Company Profile

Name
Name
Bolt Biotherapeutics Inc
Name
Phone
650-665-9295
Name
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Name
Employee
52
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
BOLT's Discussions on Twitter

Compare BOLT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BOLT
Bolt Biotherapeutics Inc
5.92 12.73M 7.88M -69.20M -69.73M -1.83
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-02-21 Initiated Guggenheim Buy
Mar-02-21 Initiated Morgan Stanley Overweight
Mar-02-21 Initiated SVB Leerink Outperform
Mar-02-21 Initiated Stifel Buy

Bolt Biotherapeutics Inc Stock (BOLT) Latest News

pulisher
Jun 12, 2025

Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Decreases By 91.6% - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Citadel Advisors LLC Makes New Investment in Kuke Music Holding Limited (NYSE:KUKE) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Citadel Advisors LLC Takes Position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

BOLT Trading Temporarily Halted as Company Awaits News | BOLT St - GuruFocus

Jun 08, 2025
pulisher
Jun 06, 2025

BOLT Trading Temporarily Halted as Company Awaits News | BOLT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Bolt Biotherapeutics Announces Reverse Stock Split - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025 - MarketScreener

Jun 06, 2025
pulisher
Jun 05, 2025

Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews

Jun 05, 2025
pulisher
Jun 05, 2025

BOLT Announcement: Bronstein, Gewirtz and Grossman, LLC Announces Investor Securities Fraud Class Action Lawsuit Filed Against Bolt Biotherapeutics, Inc - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

BOLT Announcement: Bronstein, Gewirtz and Grossman, LLC Announces Investor Securities Fraud Class Action Lawsuit Filed Against Bolt Biotherapeutics, Inc. and Chance to Actively Participate - ACCESS Newswire

Jun 03, 2025
pulisher
May 28, 2025

Bolt Biotherapeutics Approves Key Governance Changes - TipRanks

May 28, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 22, 2025

Lake Street Capital Begins Coverage on Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World

May 22, 2025
pulisher
May 20, 2025

Lake Street Initiates Coverage of Bolt Biotherapeutics (BOLT) with Buy Recommendation - Nasdaq

May 20, 2025
pulisher
May 20, 2025

BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics wit - GuruFocus

May 20, 2025
pulisher
May 20, 2025

BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics with Buy Rating | BOLT Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Lake Street Begins Coverage of Bolt Biotherapeutics (BOLT) with Bullish Outlook | BOLT Stock News - GuruFocus

May 20, 2025
pulisher
May 16, 2025

Leerink Partnrs Has Optimistic Outlook of BOLT Q2 Earnings - Defense World

May 16, 2025
pulisher
May 15, 2025

Stifel Nicolaus Lowers Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.00 - Defense World

May 15, 2025
pulisher
May 14, 2025

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 14, 2025
pulisher
May 13, 2025

BOLT Stock Target Price Revised to $1 Amid Recent Developments | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

BOLT: Stifel Lowers Price Target on Bolt Biotherapeutics, Mainta - GuruFocus

May 13, 2025
pulisher
May 13, 2025

BOLT Stock Target Price Revised to $1 Amid Recent Developments | BOLT Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Bolt Biotherapeutics Reports Q1 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 12, 2025

BOLT Exceeds Q1 Revenue Expectations with Higher Earnings | BOLT Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Inc (BOLT) Q1 2025 Earnings: EPS of -$0.29 Beats Estimate, Revenue Surpasses Expectations at $1.2 Million - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 11, 2025

Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 10, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 10, 2025
pulisher
May 08, 2025

BOLT: Surge in Interest for Bolt Biotherapeutics Amid Key Develo - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study an - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study and Financial Updates | BOLT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 ... - Eagle-Tribune

May 08, 2025
pulisher
May 08, 2025

About Us - FinancialContent

May 08, 2025
pulisher
May 04, 2025

Bolt Biotherapeutics, Inc. (BOLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire

May 04, 2025
pulisher
May 01, 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia

May 01, 2025
pulisher
Apr 30, 2025

Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

New Cancer Treatment Breakthrough: Bolt Bio's Dual-Target Therapy Achieves Complete Response in Early Tests - Stock Titan

Apr 30, 2025
pulisher
Apr 29, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 26, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times

Apr 26, 2025
pulisher
Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan

Apr 25, 2025

Bolt Biotherapeutics Inc Stock (BOLT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Bolt Biotherapeutics Inc Stock (BOLT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Quinn William P.
President, CEO and CFO
Dec 16 '24
Buy
0.50
2,500
1,241
41,272
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Cap:     |  Volume (24h):